A 3-month comparison of efficacy and safety of brimonidine-tartrate 0.2% timolol 0.5% fixed combination (BID) with timolol 0.5% (BID) or brimonidine-tartrate 0.2% (TID)

被引：0

作者：

Craven, ER

Choplin, N

Larsen, C

Olson, M

Whitcup, S

机构：

[1] Glacoma Consultants Colorado, Littleton, CO USA

[2] Eye Care San Diego, San Diego, CA USA

[3] Allergan Pharmaceut Inc, Irvine, CA USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2002年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

282

引用

页码：U54 / U54

页数：1

共 50 条

[31] Phase 3 Randomized 3-Month Trial with an Ongoing 3-Month Safety Extension of Fixed-Combination Brinzolamide 1%/Brimonidine 0.2%
Nguyen, Quang H.
McMenemy, Matthew G.
Realini, Tony
Whitson, Jess T.
Goode, Stephen M.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (03) : 290 - 297
[32] Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma
Sang Woo Park
Joon Mo Kim
Ji Woong Lee
Joy Maglambayan
Susan Simonyi
Ki Ho Park
Japanese Journal of Ophthalmology, 2021, 65 : 295 - 305
[33] Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma
Park, Sang Woo
Kim, Joon Mo
Lee, Ji Woong
Maglambayan, Joy
Simonyi, Susan
Park, Ki Ho
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2021, 65 (02) : 295 - 305
[34] Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany
Thelen, Ulrich
Buchholz, Patricia
Kimmich, Friedemann
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 1003 - 1009
[35] A six-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination BID to the concomitant administration of 0.5% timolol BID and 2.0% MK-507 BID
Chen, YF
Yang, CH
Hung, PT
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2003, 19 (05) : 417 - 423
[36] Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: A prospective, unmasked study
Tsai, JC
Chang, HW
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 21 (06) : 475 - 482
[37] A COMPARISON OF THE CARDIOVASCULAR AND PULMONARY EFFECTS OF BRIMONIDINE 0.2-PERCENT, TIMOLOL 0.5-PERCENT, AND BETAXOLOL SUSPENSION 0.25-PERCENT
PASQUALE, LR
NORDLUND, JR
ROBIN, AL
RUDIKOFF, MT
ORDMAN, J
WALT, JG
CHEN, QF
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 929 - 929
[38] A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension (vol 19, pg 37, 2003)
Mundorf, T
Williams, R
Whitcup, S
Felix, C
Batoosingh, A
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2004, 20 (04) : 372 - 372
[39] Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension
Craven, ER
Walters, TR
Williams, R
Chou, C
Cheetham, JK
Schiffman, R
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 21 (04) : 337 - 348
[40] Efficacy and safety of the fixed combination latanoprost/timolol versus the unfixed combination brimonidine/timolol in patients with elevated intraocular pressure: A 6-month, masked-evaluator study
Garcia-Sanchez, J
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U375 - U375

← 1 2 3 4 5 →